| Literature DB >> 32962710 |
P van Gerven1, J M van Dongen2, S M Rubinstein2, M F Termaat3, M El Moumni4, W P Zuidema5, P Krijnen3, I B Schipper3, M W van Tulder2,6.
Abstract
BACKGROUND: To evaluate the cost-effectiveness of a reduction in the number of routine radiographs in the follow-up of patients with ankle fractures.Entities:
Keywords: Ankle fractures; Cost-effectiveness analysis; Economic evaluation; Follow-up; Radiography; Randomised controlled trial; Routine
Mesh:
Year: 2020 PMID: 32962710 PMCID: PMC7507707 DOI: 10.1186/s12913-020-05725-1
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Patient characteristics by treatment allocation
| usual care | reduced imaging | ||
|---|---|---|---|
| (N = 128) | ( | ||
| 69 (53.9) | 58 (48.7) | ||
| 47.7 (18.5) | 50.8 (18.2) | ||
| 25.8 (4.3) | 27.3 (6.0) | ||
| 22 (17.2) | 16 (13.4) | ||
| 10 (7.8) | 9 (7.6) | ||
| 77 (60.2) | 77 (64.7) | ||
| 2 (1.6) | 2 (1.7) | ||
| 94 (73.4) | 94 (79.0) | ||
| 31 (24.2) | 23 (19.3) | ||
| 1 (0.8) | 0 (0.0) | ||
| 2 (1.6) | 2 (1.7) | ||
| 93 (72.7) | 94 (79.0) | ||
| 27 (21.1) | 21 (17.6) | ||
| 6 (4.7) | 2 (1.7) | ||
| 66 (51.6) | 64 (53.8) | ||
| 27 (21.1) | 21 (17.6) | ||
| 35 (27.3) | 34 (28.6) | ||
| 53 (41.4) | 47 (39.5) | ||
| 60 (46.9) | 55 (46.2) | ||
| 15 (11.7) | 12 (7.7) |
Abbreviations: SD Standard deviation; SA Supination-adduction; SE Supination-external rotation; PA Pronation-adduction; PE Pronation-eversion; BMI Body Mass index; ASA American Society of Anesthesiologists, available from: www.asahq.org
Fig. 1Flowchart of participants
Mean cost (in euros) per participant in the intervention and control group and mean cost differences between groups during follow-up
| Cost category | Control | Intervention | Cost difference crude, mean (95%CI) | Cost difference adjusted, mean (95%CI) |
|---|---|---|---|---|
| Intervention | 266 (9) | 222 (9) | ||
| Primary care | 967 (154) | 1266 (387) | 299 (− 170 to 1421) | 137 (− 277 to 1018) |
| Secondary care | 7435 (971) | 7803 (1176) | 368 (− 2156 to 3457) | − 169 (− 2230 to 2178) |
| Medication | 36 (9) | 27 (7) | −9 (−27 to 11) | −8 (− 27 to 12) |
| Informal care | 671 (121) | 647 (131) | −24(− 338 to 312) | −46 (− 373 to 262) |
| Absenteeism | 976 (212) | 1218 (312) | 242 (− 397 to 1008) | 306 (−373 to 1109) |
| Presenteeism | 4903 (627) | 4373 (605) | − 530 (− 2084 to 979) | −29(− 1503 to 1408) |
| Unpaid productivity loss | 789 (152) | 757 (184) | −32 (−467 to 410) | −12(− 437 to 427) |
Differences in pooled mean costs and effects (95% Confidence intervals), incremental cost-effectiveness ratios, and the distribution of incremental cost-effect pairs around the quadrants of the cost-effectiveness planes for reduced imaging compared to usual care
| Analysis | Sample size | Outcome measure | ∆C (95% CI) | ∆E (95% CI) | ICER | Distribution CE-plane (%) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Control | Intervention | € | Points | €/point | NE | SE | SW | NW | ||
| 128 | 118 | QALYs (Range: 0–1) | 131 (− 3039 to 3928) | − 0.008 (− 0.04 to 0.03) | −16,198 | 17.4 | 14.4 | 32.1 | 36.0 | |
| 128 | 118 | OMAS (Range: 0–100) | 131 (− 3039 to 3928) | 0.73 (− 5.29 to 6.76) | 178 | 21.4 | 31.8 | 15.0 | 25.8 | |
| 29 | 23 | QALYs (Range: 0–1) | 1242 (− 7949 to 6447) | −0.014 (− 0.06 to 0.04) | −86,988 | 46.0 | 7.5 | 10.9 | 35.6 | |
| 29 | 23 | OMAS (Range: 0–100) | 1242 (−7949 to 6447) | 3.04 (− 5.82 to 11.89) | 409 | 70.1 | 16.2 | 2.8 | 10.8 | |
| 128 | 118 | QALYs (Range: 0–1) | 131 (−3039 to 3947) | −0.013 (− 0.05 to 0.02) | − 10,394 | 8.3 | 15.9 | 30.8 | 45.0 | |
| 128 | 118 | QALYs (Range: 0–1) | 383 (− 2900 to 4365) | −0.008 (− 0.04 to 0.03) | −47,311 | 19.2 | 13.2 | 29.8 | 39.9 | |
| 128 | 118 | OMAS (Range: 0–100) | 383 (− 2900 to 4365) | 0.73 (− 5.29 to 6.75) | 527 | 30.6 | 28.9 | 13.2 | 27.4 | |
| 128 | 118 | QALYs (Range: 0–1) | − 89 (− 2386 to 3287) | −0.008 (− 0.04 to 0.03) | 11,052 | 14.3 | 17.2 | 36.4 | 32.1 | |
| 128 | 118 | OMAS (Range: 0–100) | −89 (−2386 to 3287) | 0.73 (−5.29 to 6.75) | −121 | 23.6 | 36.2 | 17.4 | 22.8 | |
| 51 | 41 | QALYs (Range: 0–1) | − 2425 (− 9691 to 1223) | −0.03 (− 0.09 to 0.02) | 74,883 | 3.7 | 8.1 | 66.2 | 22.0 | |
| 51 | 41 | OMAS (Range: 0–100) | −2425 (− 9691 to 1223) | − 1.60 (−10.49 to 7.30) | 1519 | 6.2 | 28.5 | 45.5 | 19.8 | |
| 77 | 77 | QALYs (Range: 0–1) | 1432 (− 3007 to 6706) | 0.001 (−0.04 to 0.04) | 1,504,404 | 39.0 | 15.5 | 14.7 | 30.9 | |
| 77 | 77 | OMAS (Range: 0–100) | 1432 (−3007 to 6706) | 1.51 (−5.07 to 8.08) | 951 | 50.6 | 24.7 | 4.3 | 20.4 | |
SA Sensitivity analysis; QALYs Quality Adjusted Life Years; OMAS Olerud and Molander Ankle Score; ∆C Difference in cost; ∆E Difference in effect; ICER Incremental Cost Effectiveness Ratio; CE- plane Cost Effectiveness plane; NE North east part of the CE-plane (representing an intervention that is more costly, but more effective); SE South east part of the CE-plane (representing an intervention that is cheaper, and more effective); SW South west part of the CE-plane (representing an intervention that is cheaper, but less effective); NW North west part of the CE-plane (representing an intervention that is both more costly and less effective)
Fig. 2Cost-effectiveness plane for QALYs, representing the results from the 5000 bootstrapped replications, and the point estimate. Higher on the Y-axis corresponds to costlier than control, more right on the X axis corresponds to more effective than control
Fig. 3Cost-effectiveness acceptability curve for QALYs, showing the probability of the intervention being cost effective at a certain willingness-to-pay value per QALY
Fig. 4Cost-effectiveness plane for OMAS, representing the results from the 5000 bootstrapped replications, and the point estimate. Higher on the Y-axis corresponds to costlier than control, more right on the X axis corresponds to more effective than control
Fig. 5Cost-effectiveness acceptability curve for OMAS, showing the probability of the intervention being cost effective at a certain willingness-to-pay value per point increase of the OMAS